Low impact
Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer
Blue Cross & Blue Shield of Mississippi·Effective Apr 17, 2025
HCPCS S3722 is officially defined as "Dose optimization by area under the curve (auc) analysis, for infusional 5-fluorouracil." HCPCS S3722 is referenced in 1 tracked payer policy change from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS S3722 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.